A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).
<h4>Background</h4>There have been increasing concerns regarding the safety and efficacy of neuroleptics in people with dementia, but there are very few long-term trials to inform clinical practice. The aim of this study was to determine the impact of long-term treatment with neuroleptic...
Main Authors: | Clive Ballard, Marisa Margallo Lana, Megan Theodoulou, Simon Douglas, Rupert McShane, Robin Jacoby, Katja Kossakowski, Ly-Mee Yu, Edmund Juszczak, Investigators DART AD |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2008-04-01
|
Series: | PLoS Medicine |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/18384230/?tool=EBI |
Similar Items
-
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial)
by: Ballard, C, et al.
Published: (2008) -
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (The DART-AD Trial)
by: Ballard, C, et al.
Published: (2008) -
A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial).
by: Ballard, C, et al.
Published: (2008) -
The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.
by: Ballard, C, et al.
Published: (2009) -
A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome.
by: Ballard, C, et al.
Published: (2004)